Biotechnology

Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2

January 18, 2022 9:25 AM

"Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2" KELOWNA, BC / ACCESSWIRE / January 18, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, comments on an independent January 10 study, available here, that discovered that "Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants". In an interview granted to...

Read more

Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor

January 18, 2022 8:00 AM

TUCSON, AZ / ACCESSWIRE / January 18, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics company with an anti-inflammatory therapeutic platform for life-threatening unchecked inflammation, has closed a $2.5M convertible note fund raise led by a $1.5M investment from JSR Life Sciences, LLC. The convertible note close brings the total Aqualung funding to date to >$17M, with $14 million derived from non-dilutive capital via NIH-funded...

Read more

Apollo Endosurgery Appoints Keely Scamperle as Vice President of Reimbursement and Market Access

January 18, 2022 7:45 AM

Veteran Leader Brings 25 Years of Global Medical Device Experience AUSTIN, TX / ACCESSWIRE / January 18, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the hiring of Keely Scamperle as Vice President, Reimbursement & Market Access, effective January 17, 2022. "At Apollo, we are addressing large unmet clinical needs in...

Read more

EV Biologics Updates on FINRA

January 18, 2022 7:00 AM

NASHVILLE, TN / ACCESSWIRE / January 18, 2022 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders with further details about its submitted FINRA applications for name change and NFT dividend distribution. The Company is still awaiting approval from FINRA for the NFT dividend distribution. This is the first time that any public company has attempted to distribute a NFT digital asset as a dividend. Upon approval from FINRA, the Company...

Read more

CB Scientific, Inc. Concludes Its Special Meeting of Stockholders

January 18, 2022 6:00 AM

Commanding shareholder approval better positions management to attain enterprise business objectives going forward ESCONDIDO, CA / ACCESSWIRE / January 18, 2022 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") announced today that the company successfully concluded its Special Meeting of Stockholders ("Special Meeting") on Friday, January 14, 2022, as planned. Votes representing approximately 73% of the total eligible shares were...

Read more

BioInvent Appoints Experienced Industry Leader Marie Moores as Chief Operating Officer

January 18, 2022 2:50 AM

LUND, SWEDEN / ACCESSWIRE / January 18, 2022 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces the appointment of Marie Moores as Chief Operating Officer. Marie Moores joins the company on February 1, 2022, and she will be involved in all operational aspects including...

Read more

Hillstream BioPharma Announces Closing of Initial Public Offering

January 14, 2022 4:00 PM

BRIDGEWATER, NJ / ACCESSWIRE / January 14, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced the closing of its initial public offering of 3,750,000 shares of the Company's common stock at a public...

Read more

Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa

January 14, 2022 8:00 AM

BOSTON, MA / ACCESSWIRE / January 14, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the first patient has been dosed in the phase 2 study of cinrebafusp alfa (PRS-343), a 4-1BB/HER2 Anticalin-based bispecific for the treatment of...

Read more

Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors

January 13, 2022 8:30 AM

SAN DIEGO, CA / ACCESSWIRE / January 13, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focused on the treatment of medical and aesthetic skin conditions, today announced the appointment of Brittany Bradrick to its Board of Directors and its Audit Committee. "I am excited to welcome Brittany to our Board of Directors," commented Gerry Proehl, Dermata's Chief Executive...

Read more

Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy

January 13, 2022 7:55 AM

Phase 3 study will focus on critically ill patients, many of whom have run out of effective drug treatment options TORONTO, ON / ACCESSWIRE / January 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that the company has received approval from Health Canada to test its monoclonal antibody candidate, designated EB05, as a rescue therapy for...

Read more

Fastest Human Genome Sequence Uses Oxford Nanopore

January 13, 2022 2:00 AM

Scientists describe new approach in NEJM, using Oxford Nanopore DNA sequencing technology to improve prognosis in critically ill patients, in less than 8 hours Oxford Nanopore worked with a team led by Stanford University School of Medicine in a research study to develop a rapid, whole genome sequencing approach, that: Improves prognosis in critically ill patients and guides clinical management at least as well as current short read...

Read more

Fastest Human Genome Sequence Uses Oxford Nanopore

January 13, 2022 2:00 AM

Scientists describe new approach in NEJM, using Oxford Nanopore DNA sequencing technology to improve prognosis in critically ill patients, in less than 8 hours Oxford Nanopore worked with a team led by Stanford University School of Medicine in a research study to develop a rapid, whole genome sequencing approach, that: Improves prognosis in critically ill patients and guides clinical management at least as well as current short read...

Read more

Asia Green Biotechnology Corp. Closes Financing to Proceed with Research Activities

January 11, 2022 8:25 PM

CALGARY, AB / ACCESSWIRE / January 11, 2022 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company") (CSE:ASIA) announced today that it has closed the previously announced financing arrangement with a director of the Company. The funds raised under this arrangement will be used for the purpose of addressing certain expenses tied to ongoing research activities being conducted or which may be commenced by the Company pursuant to the terms...

Read more

Hillstream BioPharma Announces Pricing of Initial Public Offering

January 11, 2022 7:55 PM

BRIDGEWATER, NJ / ACCESSWIRE / January 11, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced the pricing of its initial public offering of 3,750,000 shares of the Company's common stock at a public...

Read more

Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial

January 11, 2022 8:00 AM

VERO BEACH, FL / ACCESSWIRE / January 11, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the completion of dosing of the second cohort of patients involved in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a...

Read more

Apollo Endosurgery Announces Preliminary 2021 Revenue Results; Reflecting 50% Growth Over 2020

January 10, 2022 4:05 PM

Fourth quarter 2021 revenue grew 25% over 2020 AUSTIN, TX / ACCESSWIRE / January 10, 2022 / Apollo Endosurgery, Inc. ("Apollo" or the "Company") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced preliminary unaudited revenue results for the fourth quarter and full year ended December 31, 2021. Preliminary, Unaudited 2021 Revenue Quarter Ended December 31, 2021 Year...

Read more

Oncology Pharma's New Year Update

January 10, 2022 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") update on its progress to kick off the new year. The Company has advanced its relationship and made further investment into Ribeira Solutions' Connect2Med, a patient engagement platform utilizing latest available technologies. Connect2Med provides a motivating trial experience through increased engagement and easy to...

Read more

Lumira Ventures Announces Promotion of Lu Han, Ph.D. to Partner and Team Expansion

January 6, 2022 7:00 AM

TORONTO, ON / ACCESSWIRE / January 6, 2022 / Lumira Ventures, a leading North American healthcare venture capital firm, today announced the promotion of Dr. Lu Han, Ph.D., to Partner and the appointments of Dr. Suman Rao, Ph.D. as an Associate and Dr. Ai Li (Alice) Luo, Ph.D. as an Analyst. This expansion of the Lumira Ventures investment team follows a year in which the firm raised over US$370 million (C$450 million) via three new investment...

Read more

Applied UV Announces Full Exercise of Over-Allotment Option in Underwritten Public Offering

January 5, 2022 11:35 AM

MOUNT VERNON, NY / ACCESSWIRE / January 5, 2022 / Applied UV, Inc. (NASDAQ:AUVI) (NASDAQ:AUVIP) ("Applied UV" or the "Company"), an industry leader in air and surface pathogen elimination technology, today announced that the underwriters of its previously completed underwritten public offering have exercised their over-allotment option to purchase an additional 400,000 shares of Common Stock, for aggregate gross proceeds of approximately $1.2...

Read more

Cantabio Pharmaceuticals Awarded Grant From The Michael J. Fox Foundation to Develop Novel Small-Molecule Aggregation Inhibitors of the Tau Protein for the Treatment of Parkinson’s Disease

January 5, 2022 10:15 AM

Grant enables the further development of Cantabio's novel small-molecule tau protein aggregation inhibitors, which have high therapeutic potential in both disease-modifying and preventive contexts for the treatment of Parkinson's and Alzheimer's disease. PALO ALTO, CA / ACCESSWIRE / January 5, 2022 / Cantabio Pharmaceuticals, Inc. ("Cantabio" or the "Company"), a preclinical stage pharmaceutical company developing disease-modifying therapeutics...

Read more